Introduction {#s1}
============

Asthma continues to be a major public health concern world­wide \[[@R01]\], as it presently affects more than 300 million individuals, generating a substantial burden for both patients and the healthcare system \[[@R02]\]. Yet, despite its socioeconomic significance, asthma prevalence trends among adults for the preceding decade, as well as data on allergic asthma and non-allergic asthma as separate conditions, are lacking.

Nonetheless, Backman reported an increase in the prevalence of allergic asthma from 5% in 1996 to 7.3% in 2016, while noting minimal changes in the prevalence of non-allergic asthma (3.4-3.8%) in the same period \[[@R03]\]. According to a recent Jordanian study, in 2018, asthma was diagnosed in 6.2% adolescents in northern Jordan \[[@R04]\].

Genetic \[[@R05]\], develop­mental and environmental factors, such as viral infections \[[@R06]\] and occupational exposure \[[@R07]\], have been associated with asthma susceptibility, age at onset and severity. Although disease pathogenesis has not been fully elucidated, development of an immune response to al­lergens is recognized as a major risk factor \[[@R08]\].

The Global Initiative for Asthma (GINA) guidelines provide two asthma classification systems \[[@R9]\], based respectively on severity (intermittent, mild persistent, moderate persistent or severe persistent) and on asthma control level (controlled, partly controlled or uncontrolled) \[[@R9]\]. The latter, more recent, classification is preferred in clinical practice.

Although asthma control can be assessed via a variety of validated questionnaires, asthma control questionnaire (ACQ) Juniper is most widely used. Its longer form takes into account day and night symptoms and a β~2~-agonist as needed, as well as the baseline airway caliber measured by forced expiratory volume in 1 s (FEV1) \[[@R10]\]. Several shortened versions are also in use, in which either the FEV1 item and/or the β~2~-agonist consumption item are omitted, as they have been shown to provide similar information on the level of asthma control achieved by treatment \[[@R11]\].

However, in spite of these new guidelines, according to population studies conducted in the past decade, asthma control remains elusive for the majority of patients \[[@R12]\], even though mild to moderate asthma is the most prevalent and should respond to modern therapeutic regimens \[[@R13]\]. Findings yielded by the asthma control and treatment (REACT) study focusing on US patients with moderate to severe asthma receiving standard asthma medications noted that 55% of the sample failed to achieve asthma control \[[@R12]\]. This is a serious issue, as uncontrolled asthma can lead to morbidity, while reducing professional achievement potential \[[@R14]\] and increasing medical resource expenditure \[[@R15]\]. Therefore, it is important to understand the risk factors for uncontrolled asthma.

The level of asthma control and its relationship with asthma severity and atopy is complex and the importance of the intensity of allergic sensitization to asthma severity is presently poorly understood. However, most extant studies examining these issues focused on children and yielded inclusive findings. Thus, in the present cross-sectional study, the sample comprises of a cohort of adult asthma patients recruited from the respiratory clinic in Prince Ali Military Hospital, Al-Karak. The primary aim of this study was to elucidate the degree of asthma control in Jordanian adult patients and to evaluate atopy, asthma severity and other risk factors associated with poorly controlled asthma in this cohort.

Materials and Methods {#s2}
=====================

Data collection {#s2a}
---------------

The present study was approved by the Ethics and Scientific Committees of the Faculty of Medicine at Mutah University prior to administering the self-completed questionnaires. The study was performed during 2012 - 2013 on patients attending asthma clinic without excluding those who were already receiving inhaled corticosteroid treatment, current smokers or those experiencing an asthma exacerbation at the time of the investigation. Thus, the study sample included newly diagnosed asthmatics, as well as patients with a well-established diagnosis whose disease duration was variable.

Patient characteristics {#s2b}
-----------------------

Information on sex, age, body mass index (BMI), educational attainment, asthma duration, current medication and symptoms was collected from all patients, and personal and family history of allergy, personal history of any other co-morbid diseases, including hypertension, heart disease and diabetes were collected under the name of history of any ongoing chronic disease. Smoking history and history of influenza vaccination were also obtained. Atopy was defined as having a positive skin prick test (SPT).

Assessment of asthma control and severity {#s2c}
-----------------------------------------

All patients that agreed to take part in the study were administered a five-item questionnaire assessing their asthma symptoms, use of rescue medications and the impact of asthma on daily life \[[@R16]\]. They were also administered an asthma control test, whereby a score of ≥ 25, 20 - 24, 16 - 19 and ≤ 15 points indicated full control, control, partial control and uncontrolled disease, respectively. However, for statistical analyses, only two groups were formed, respectively comprising of patients that scored above and below 20 points. This threshold was chosen as the ACT score \< 20 was confirmed in previous studies as a useful threshold for identifying patients with poorly controlled asthma, as defined by GINA \[[@R17]\].

According to the GINA criteria \[[@R18]\], spirometry test results, asthma symptoms and medication use (especially doses of inhaled corticosteroids) are typically used in clinical practice to classify patients into four groups according to asthma severity (intermittent, mild persistent, moderate persistent or severe persistent).

Allergy skin tests {#s2d}
------------------

Once the informed consent was obtained from patients that agreed to partake in the study, they were subjected to the SPT, which included all common inhalant allergens, namely *Dermatophagoides pteronyssinus* (*Dp*) and *Dermatophagoides farinae* (*Df*) house dust mite (HDM), olive pollen, cat dander, dog dander, compositae, wall pellitory, salsola kali, four cereals, 12 grasses and mold, along with positive control (histamine) and negative control (vehicle) (Stallergenes, France), in accordance with published guidelines \[[@R19]\]. Atopy was defined as having an allergen-induced wheal reaction equal to or great­er than that caused by histamine (1 mg/mL) or exceeding 3 mm in diameter.

Statistical analyses {#s2e}
--------------------

As the data were not normally distributed, based on the findings of the Kolmogorov-Smirnov test (P \< 0.05), non-parametric analysis was performed using Mann-Whitney U test, and mean and standard errors were also calculated. Categorical variables were analyzed using the Chi-squared test. However, Fisher's exact test was performed when \> 20% of the expected frequencies were below 6. Multi-logistic regressions were conducted to calculate adjusted odds ratio (AOR) and 95% confidence intervals (95% CIs) to assess the relationship between risk factors and uncontrolled disease, including the potential confounders. A P-value below 0.05 was considered statistically significant. In these analyses, patients with partly controlled and uncontrolled asthma were combined into one group denoted as "poorly controlled asthma". Independent variables that were statistically significantly associated with asthma control in the univariate analyses were included in the multivariate analyses. All the analyses were performed using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA).

Results {#s3}
=======

Sample characteristics {#s3a}
----------------------

The study sample comprised of 93 asthmatic adults aged 40.5 ± 13.6, 36.6% of whom were male and 63.4% were female. The average amount of time patients had suffered from asthma was 7.3 ± 7.9 years and the average mean BMI was 27.6 ± 5.0. Allergy SPT was positive in 54 (58.1%) cases. Although 72 (77.4%) patients were receiving asthma treatment, asthma control was achieved in only 45.2% of the sample. Moreover, 66.7%, 49.5%, 5.4%, 25.8% and 28% of the patients self-reported allergic rhinitis (hay fever), allergic conjunctivitis, food allergy, atopic dermatitis and chronic disease including any of hypertension, heart disease or diabetes, respectively. The history of smoking and influenza vaccination was reported by 72% and 70% of the sample, respectively. GINA classification of asthma severity is summarized in [Table 1](#T1){ref-type="table"}, indicating that in Jordan asthma is most commonly treated using inhaled β~2~-agonist, followed by inhaled corticosteroids and lastly oral β~2~-agonist.

###### Characteristics of the Study Population

  Variable                               Mean ± SD      Number (N = 93)   Percentage
  -------------------------------------- -------------- ----------------- ------------
  Weight (kg)                            73.25 ± 13.3                     
  Height (cm)                            163.3 ± 9.6                      
  Body mass index (kg/m^2^)              27.6 ± 5.0                       
  Age (years)                            40.5 ± 13.6                      
  Duration of asthma diagnosis (years)   7.3 ± 7.9                        
  Gender                                                                  
    Male                                                34                36.6
    Female                                              59                63.4
  Atopy                                                                   
    Positive                                            54                58.1
    Negative                                            39                41.9
  Allergic to two or more allergens                     33                35.5
  Allergic to three or more allergens                   13                14
  Mean asthma control test score         16.6 ± 6.0                       
  Asthma control test                                                     
    Controlled                                          42                45.2
    Partially controlled                                17                18.3
    Uncontrolled                                        34                36.6
  GINA classification                                                     
    Intermittent                                        28                30.1
    Mild persistent                                     40                43.0
    Moderate persistent                                 20                21.5
    Severe persistent                                   5                 5.4
  Smoking history                                                         
    Positive                                            26                28
    Negative                                            67                72
  Influenza vaccination history                                           
    Positive                                            28                30.1
    Negative                                            65                69.9
  Comorbidity                                                             
    Allergic rhinitis                                   62                66.7
    Allergic conjunctivitis                             46                49.5
    Food allergy                                        5                 5.4
    Eczema                                              24                25.8
    Other chronic disease                               26                28
  Presence of chronic disease                                             
    Yes                                                 26                28
    No                                                  67                72
  Treatment                                                               
    Inhaled corticosteroids                             36                38.7
    Oral β~2~-agonist                                   19                20.4
    Inhaled β~2~-agonist                                62                66.7
    No treatment                                        21                22.6

GINA: Global Initiative for Asthma; SD: standard deviation.

Characteristics of patients with controlled, partially controlled and uncontrolled asthma {#s3b}
-----------------------------------------------------------------------------------------

As previously explained, patients with partly controlled and uncontrolled asthma were combined into the "poorly controlled asthma" group. In the age group ≥ 55 years, all patients had uncontrolled asthma, while this was the case for only 37.7% of those aged \< 55 years (P = 0.0), as shown in [Table 2](#T2){ref-type="table"}. Asthma duration in the "uncontrolled" and "controlled" group was 8.8 and 5.4 years, respectively, and the difference was statistically significant at P of 0.037 (data not shown). Being atopic to one or more allergens was statistically significantly associated with uncontrolled asthma. Moreover, having allergic rhinitis alongside asthma was related to a greater likelihood of poor asthma control ([Table 3](#T3){ref-type="table"}). The proportion of patients who were on treatment for asthma were significantly higher in the uncontrolled asthma than controlled asthma groups (P = 0.02).

###### Baseline Characteristics of the Overall Sample for Controlled, Partly Controlled and Uncontrolled Asthma

                                         Controlled asthma (n, %)   Partly controlled asthma (n, %)   Uncontrolled asthma (n, %)   P
  -------------------------------------- -------------------------- --------------------------------- ---------------------------- -------
  Total study group (n = 93)                                                                                                       
  Sex                                                                                                                              
    Female                               27 (29)                    13 (14)                           19 (20.4)                    
    Male                                 15 (16.1)                  4 (4.3)                           15 (16.1)                    
  Age group                                                                                                                        0.00
    \< 55 years                          42 (45.2)                  14 (15.1)                         21 (22.6)                    
    ≥ 55 years                           0                          3 (3.2)                           13 (14)                      
  Body mass index (kg/m^2^)                                                                                                        
    \< 30                                30 (32.3)                  14 (15.1)                         24 (25.8)                    
    ≥ 30                                 12 (12.9)                  3 (3.2)                           10 (10.8)                    
  Duration of asthma diagnosis (years)   5.4                        7.1                               9.7                          0.037
  Atopy                                                                                                                            0.00
    Positive                             12 (12.9)                  13 (14)                           29 (31.2)                    
    Negative                             30 (32.3)                  4 (4.3)                           5 (5.4)                      
  Allergic to two or more allergens      4 (4.3)                    9 (9.7)                           20 (21.5)                    0.00
  Allergic to three or more allergens    2 (2.2)                    2 (2.2)                           9 (9.7)                      0.024
  Comorbidity                                                                                                                      0.015
    Allergic rhinitis                    23 (24.7)                  10 (10.8)                         29 (31.2)                    
    Allergic conjunctivitis              22 (23.7)                  12 (12.9)                         12 (12.9)                    
    Food allergy                         1 (1.1)                    2 (2.2)                           2 (2.2)                      
    Eczema                               9 (9.7)                    7 (7.5)                           8 (8.6)                      
    Other chronic disease                10 (10.8)                  3 (3.2)                           13 (14)                      
  History of smoking                                                                                                               
    Positive                             12 (12.9)                  4 (4.3)                           10 (10.8)                    
    Negative                             30 (32.3)                  13 (14)                           24 (25.8)                    
  Presence of chronic disease                                                                                                      
    Yes                                  10 (10.8)                  3 (3.2)                           13 (14)                      
    No                                   32 (34.4)                  14 (15.1)                         21 (22.6)                    
  History of flu-vaccine                                                                                                           
    Positive                             14 (15.1)                  5 (5.4)                           9 (9.7)                      
    Negative                             28 (30.1)                  12 (12.9)                         25 (26.9)                    
  Treatment                                                                                                                        0.02
    Yes                                  28 (30.1)                  17 (18.3)                         27 (29)                      
    No                                   14 (15.1)                  0                                 7 (7.5)                      

Absolute number and percentage in brackets.

###### Frequency of GINA-Based Asthma Severity Cases in the Controlled and Uncontrolled Asthma Groups

  GINA                  Asthma control test   Chi-squared   P       
  --------------------- --------------------- ------------- ------- ------
  Intermittent          20 (21.5%)            8 (8.6%)      20.97   0.00
  Mild persistent       19 (20.4%)            21 (22.6%)            
  Moderate persistent   1 (1.1%)              19 (20.4%)            
  Severe persistent     2 (2.2%)              3 (3.2%)              

Absolute number and percentage in brackets. GINA: Global Initiative for Asthma.

GINA-based asthma severity in patients with controlled and uncontrolled asthma {#s3c}
------------------------------------------------------------------------------

Based on the GINA classification of asthma severity, 30.1% of the asthma patients included in the study had intermittent asthma, 43.0% had mild persistent asthma, 21.5% had moderate persistent asthma and 5.4% had severe persistent asthma. According to the asthma control test, uncontrolled asthma was noted in 22.6%, 20.4% and 3.2% of mild persistent, moderate persistent and severe persistent, respectively ([Fig. 1](#F1){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). Moreover, control was achieved in 71.4% of patients diagnosed with intermittent asthma, whereby the association between asthma severity and absence of control was statistically significant (χ^2^ = 20.97; P \< 0.05), as shown in [Table 3](#T3){ref-type="table"}.

![Frequency of GINA-based asthma severity cases in the controlled and uncontrolled asthma groups. GINA: Global Initiative for Asthma.](jocmr-11-807-g001){#F1}

Frequency of positive SPTs by aeroallergen type {#s3d}
-----------------------------------------------

The SPT was positive to one or more allergens in 54 (58.1%) cases. In these patients, the most common offending allergen was olive pollen, followed by HDM and cat dander ([Fig. 2](#F2){ref-type="fig"}). Moreover, allergic sensitization was noted in 45.2% of the uncontrolled group, which was significantly higher than 12.9% noted for the controlled group ([Table 2](#T2){ref-type="table"}). Uncontrolled asthma was statistically significantly associated with cat dander, salsola kali, *Df*, cereals, olive pollens and grasses (P \< 0.05) ([Fig. 2](#F2){ref-type="fig"}).

![The frequency of aero-allergen sensitivity in controlled and uncontrolled asthma groups.](jocmr-11-807-g002){#F2}

Comorbid allergic disease and other chronic diseases {#s3e}
----------------------------------------------------

Comorbid conditions noted in our patient co­hort included allergic rhinitis (66.7%), allergic conjunctivitis (49.5), food allergy (5.4%), eczema (25.8%) and other chronic diseases such as hypertension, diabetes and heart diseases (28%). Patients with poorly controlled asthma were significantly more likely to suffer from allergic rhinitis than were those whose asthma was well controlled (P = 0.015), as shown in [Table 2](#T2){ref-type="table"}.

Pharmacological treatments utilized by the asthmatic patients {#s3f}
-------------------------------------------------------------

In the uncontrolled asthma group, the proportions of patients who used inhaled corticosteroids (ICS), long-acting inhaled β~2~-agonist (LABA) and/or oral short-acting β~2~-agonist were non-significantly higher than in the controlled asthma group ([Fig. 3](#F3){ref-type="fig"}). Moreover, while some patients received more than one treatment, inhaled LABAs were most commonly prescribed pharmacological treatment, followed by ICSs and oral β~2~-agonist.

![Asthma treatment with inhaled corticosteroids, inhaled β~2~-agonist and oral β~2~-agonist in the controlled and uncontrolled asthma groups.](jocmr-11-807-g003){#F3}

Furthermore, no SPT suppression was achieved with the drugs patients were taking, as the percentage of patients receiving ICS who had positive and negative allergy test was the same (P \> 0.05) ([Table 4](#T4){ref-type="table"}).

###### Frequency of Positive Allergy Tests for Patients Taking and Not Taking Inhaled Corticosteroids

  Allergy test   Inhaled corticosteroids   Chi-squared   P       
  -------------- ------------------------- ------------- ------- ---------
  Negative       33 (61.1)                 21 (38.9)     0.002   \> 0.05
  Positive       24 (61.5)                 15 (38.5)             

Absolute number and percentage in brackets.

Risk factors for uncontrolled asthma {#s3g}
------------------------------------

Univariate analysis revealed that age above 55 years, presence of allergic rhinitis, presence of atopy or atopy to two or more allergens, severe asthma according to the GINA guidelines, long duration of asthma disease and being on treatment were the main risk factors associated with uncontrolled asthma. Subsequent multiple logistic regression (MLR), after adjusting for the aforementioned confounding variables, showed that asthma severity (P = 0.047) and atopy to two or more allergens (P = 0.00) were the only factors that were statically significantly related to uncontrolled asthma, for which the ORMH of 17.2 and 2.2 was obtained, respectively ([Table 5](#T5){ref-type="table"}).

###### Factors Associated With Uncontrolled Asthma Obtained via MLR Analysis

  Variable                                    Adjusted OR   95% CI (OR)      χ^2^ Stat. (df)   P
  ------------------------------------------- ------------- ---------------- ----------------- -------
  GINA                                        2.2           1.011 - 4.714    4.0               0.047
  Allergy positive to two allergens or more   17.2          4.301 - 68.702   16.2              0.00

MLR: multiple logistic regression; GINA: Global Initiative for Asthma; OR: odds ratio; CI: confidence interval.

Discussion {#s4}
==========

Low levels of asthma control are reported in many countries worldwide \[[@R12]\].

Moreover, only 30% of the adult patients that took part in a recent Jordanian study were reported to have achieved asthma control \[[@R20]\]. A study from northern of Jordan showed that smoking is the main cause of poor asthma control in adolescent\[[@R04]\] and two studies from Jordan attributed poor control to non-adherence or improper use of inhalers \[[@R21], [@R22]\]; moreover one study showed a significant association between the level of asthma control and genetic in Arab population \[[@R23]\]. However, this issue is rarely investigated in the south of Jordan and the burden of uncontrolled asthma on patients is largely unknown.

A large-scale cross-sectional epidemiological study conducted by EMSA (Assessment of Asthma Control in Adult Asthma Population in the Middle East and North Africa) in 2018 revealed that less than one-third of asthma patients achieved adequate control, which was attributed to poor mediation adherence, active smoking, absence of medical insurance, lower level of education, or long disease duration prior to seeking treatment \[[@R24]\]. These findings indicate that treatment access and medication adherence, along with better follow-up and education among healthcare providers and patients is needed to achieve greater asthma control. In the USA, on the other hand, female sex, low educational attainment, inadequate household income and certain comorbidities (such as sinusitis) emerged as the most relevant predictive factors of uncontrolled asthma \[[@R12]\].

The results yielded by the present study suggest that, in Jordan, older age (\> 55 years), atopy to two or more allergens, comorbid allergic rhinitis, being on treatment and asthma duration are the most significant factors contributing to the likelihood of uncontrolled asthma.

These findings are highly relevant, as elderly patients tend to have concomitant diseases and are therefore prescribed a wide range of medications, which leads to an increased risk of reduced treatment adherence \[[@R25]\]. Aging is also associated with a decline in immune defenses \[[@R26]\]. Elderly individuals might also have lower expectations about the degree of control that can be achieved \[[@R27]\]. Interestingly, it has also been reported that the response to β~2~-agonists declines with age due to a decreased number of β~2~-receptors in smooth muscle tissue \[[@R28]\].

Yet despite the growing recognition of atopy as a risk factor for the development of asthma, its association with uncontrolled asthma in adults remains poorly understood \[[@R29]\].

Authors that have conducted cluster analysis of asthma phenotypes tend to concur that various clusters of patients with atopy are quite heterogeneous in terms of symptom severity, pulmonary function and tendency for exacerbations. However, Kampe identified being female and having early childhood onset asthma as the main risk factors for severe adult asthma \[[@R30]\].

Furthermore, Jaakkola and co-workers \[[@R31]\] found that atopy is a strong determinant of asthma in adulthood, suggesting that atopy reduction could significantly reduce the prevalence of adult asthma. Nonetheless, the link between the intensity of allergic sensitization and asthma severity remains unclear. Peat and colleagues \[[@R32]\] found linear relationships between dust mite wheal size and asthma severity. Sarpong and colleagues \[[@R33]\] similarly found a positive association between number of positive SPTs and asthma severity evaluated by FEV~1~ and medication usage. On the other hand, asthma severity was relatively similar in skin test-negative and skin test-positive groups \[[@R34]\].

Findings yielded by the present study indicate that sensitivity to two or more aero-allergens is a risk factor for the development of uncontrolled asthma, supporting the previously published results \[[@R35]\]. The specific allergens that were found to be significantly associated with uncontrolled asthma in Jordanian patients were cat dander, salsola kali, *Df*, cereals, olive pollens and grasses. As these results are also supported by available evidence, environmental allergen avoidance is likely to alleviate some of the asthma symptoms \[[@R36], [@R37]\]. However, further investigations are needed to ascertain whether practical avoidance measures are sufficient to achieve improvement in asthma control.

Although it is possible that skin test responses were suppressed by high doses of corticosteroids (oral or inhaled) in our patient cohort, no association between lack of skin test responses and treatment with oral corticosteroids (OCSs) was noted. In extant studies, skin test responses were noted in many cases despite chronic administration of OCSs \[[@R38]\].

Several studies demonstrated that allergic rhinitis is a risk factor for poorer asthma control and more severe asthma symptoms \[[@R39]\]. For example, \> 50% of adult patients with asthma that took part in the REACT study experienced hay fever and allergic rhinitis \[[@R40]\]. Moreover, Cazzola et al \[[@R41]\] reported that allergic rhinitis was the most frequent comorbid condition suffered by Italian adults with asthma, affecting 19.7% individuals, whereas a much higher prevalence (60-80%) was noted in Korea \[[@R42]\], where this condition was also closely associated with more frequent asthma attacks, emergency room visits and poor asthma control \[[@R43]\].

Longer asthma duration is frequently linked with poor disease control due to irreversible airflow obstruction. Asthma is a chronic disease with diverse clinical manifestations that favor T helper type 2 (TH2) response, whereby interleukins lead to the formation of immunoglobulin (Ig) E, pro-inflammatory cytokines and bronchial hyper-reactivity \[[@R44]\]. T cells, derived cytokines, IgE and mast cells initiate early asthmatic reaction and recruitment, whereby eosinophil activation was posited to play a role in the persistent asthma phenotype characterized by chronic airflow obstruction \[[@R45]\], which becomes irreversible after living with the disease for a long time.

In several extant studies, moderate level of agreement between ACT and GINA asthma control classifications was obtained \[[@R46]\]. In contrast, in the present study, this association was significant. Discrepancies between the ACT classification and GINA classification of asthma control noted in some earlier studies could be explained by variability in item content and grading between the ACT and GINA definitions \[[@R17]\].

Poor adherence is a recognized risk factor for poor asthma control \[[@R47]\]. Although in the present study, the proportion of patients who used inhaled corticosteroids (ICS), long-acting inhaled β~2~-agonist (LABA) and/or oral short-acting β~2~-agonist were non-significantly higher in the uncontrolled asthma than in the controlled asthma group, being on treatment has a significant association with uncontrolled asthma. Moreover, in our patient cohort, as common in low-income countries, short-acting β~2~-agonist (SABA) was the most frequent form of treatment even though it has lower efficacy and safety \[[@R48]\].

Improved knowledge of asthma control and predictive factors is needed to address this major public healthcare burden in Jordan.

The present study findings confirm that, even in low-income countries, a simple assessment tool such as the ACT can be utilized to screen patients and categorize asthma control. This approach would facilitate a better treatment plan and is likely to contribute to greater asthma control. As absence of spirometer in many clinical settings is one of the barriers to asthma control assessment \[[@R49]\], it is essential to provide them in all health facilities. Nonetheless, if spirometer is not available, general practitioners in primary settings can use ACT. Despite the efficacy of such procedure, its effectiveness should be verified in actual primary health condi­tions to ensure comparable level of correlation among parameters.
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